Introduction:
Thrombophilia is a hemostatic condition characterized by an increased risk of thrombosis. It is possible to inherit or develop this predisposition. This review addresses indications for testing and lists common hereditary and acquired thrombophilic disorders. The conclusion is that while testing for inherited thrombophilic diseases is unlikely to be beneficial, testing for acquired thrombophilic conditions should be considered in all cases of venous thrombosis. If testing for inherited thrombophilia is to be done, consideration should be given to the advantages, disadvantages, and unintended implications of doing so.
What Is Thrombophilia?
A blood condition called thrombophilia increases the risk of blood clots in the veins and arteries. Blood clots or coagulates more readily in this disease, which medical professionals call "hypercoagulable." The inclination to produce blood clots in veins and arteries can be acquired (thrombophilia) or inherited (genetic). Normally, when an individual gets a cut on the finger, the body forms a blood clot. The blood clot halts the bleeding. When the body no longer needs the clot, it breaks it apart. The body either produces too many blood clots or fails to break down the existing ones while having thrombophilia.
Veins and arteries can become clogged or blocked due to blood clots. Because the blood vessels deliver the oxygen to the cells in need, this can damage main organs or result in a heart attack or stroke. Blood cannot reach the cells when there is an obstruction in the blood artery.
What Are the Types of Thrombophilia?
Thrombophilia comes in two flavors: the genetic variety inherited from birth and the acquired one acquired through other means.
-
Acquired Thrombophilia: Compared to genetic thrombophilia, acquired thrombophilia is more prevalent and can be caused by several factors, including medications, lifestyle choices, and illnesses. Antiphospholipid syndrome (a syndrome is a condition in which the immune system mistakenly creates antibodies that attack tissues in the body)is the most prevalent and severe kind of acquired thrombophilia.
-
Genetic Thrombophilia: One can inherit the genetic form of thrombophilia from one or both parents. Due to the mutated gene, the body produces specific clot-forming proteins that malfunction. Individuals may be unable to manufacture enough necessary protein to halt clotting due to specific genetic abnormalities.
What Are the Types of Genetic Thrombophilia?
-
Factor V Leiden Thrombophilia: The most prevalent form is hereditary thrombophilia, which affects one percent to five percent of the population. Individuals of this kind are more likely to experience a first-event deep vein thrombosis (DVT) (a serious condition in which a blood clot forms in a deep vein inside the body) but are less likely to experience subsequent blood clots.
-
Prothrombin Thrombophilia: Affected by one percent to five percent of the general population, prothrombin thrombophilia is the second most frequent kind of hereditary thrombophilia.
-
Protein C Insufficiency: Less than one percent of persons suffer from a less frequent type of protein C insufficiency. The chance of developing blood clots again is increased if one has this kind of thrombophilia.
-
Protein S Insufficiency: Less than one percent of persons suffer from a less frequent type of protein S insufficiency. In newborns, an even rarer variant (from both parents) might result in a potentially fatal clotting problem.
-
Protein Z Deficiency: This kind can raise the chance of thromboembolisms and problems during pregnancy, such as hypertension and miscarriage.
-
Antithrombin Deficiency: A less prevalent form of antithrombin deficiency, affecting one in 500 to 5,000 individuals. However, compared to those with other inherited blood clotting diseases, those who have it are more likely to experience blood clots.
What Are the Indications of Thrombophilia Testing?
Testing for clinical diagnostic thrombophilia has no set indications. Certain populations that are potentially "enriched" for thrombophilia (for example, asymptomatic or symptomatic family members of patients with a known familial thrombophilia, especially first-degree relatives) or populations at increased risk for thrombosis (for instance, before pregnancy, oral contraceptive or estrogen therapy, high-risk surgery, chemotherapy with angiogenesis inhibitors) could be selected for screening, as well as testing symptomatic patients with incident or recurrent thrombosis. These potential relative indications include general population screening and testing particular populations. These potential indications are debatable and must be weighed against the clinical presentation, except for general population screening, which is not advised.
What Tests Are Performed for Thrombophilia Testing?
What is on a thrombophilia screen is:
-
Antithrombin, formerly known as antithrombin III.
-
Factor V Leiden.
-
Protein C.
-
Protein S.
-
Lupus anticoagulant.
-
Mutations in the prothrombin gene.
-
Anti-β-2-Glycoprotein-1.
-
Anti-Cardiolipin antibodies.
Thrombophilia is a general medical word used to characterize a complex condition in which blood is more likely to clot and is therefore referred to as hypercoagulable. This disorder may be acquired, inherited, or a combination of the two, and it can increase an individual's chance of developing pathological thrombosis. The thrombophilia screening aims to identify inherited deficits of the naturally occurring anticoagulants protein C, protein S, and antithrombin. The thrombophilia screening includes antibodies linked to antiphospholipid syndrome, lupus anticoagulant, and the well-established link between the prothrombin gene and Factor V Leiden mutations and an elevated risk for venous thrombosis.
Individuals with thrombophilia may exhibit thrombosis in the veins or the arteries. In some situations, the location of thrombi can affect laboratory tests. For instance, arterial thrombosis is typically caused by a platelet or vascular disease, whereas venous thrombosis is typically linked to a lack of anticoagulant activity. Thrombosis can happen in the venous and arterial systems in patients with thrombophilia due to a lupus anticoagulant. On the other hand, arterial thrombosis is a common presentation for patients who lack protein S. Genetic causes might manifest in odd areas such as the mesenteric, hepatic, portal, or cerebral circuits. For example, a factor V Leiden (FVL) mutation can produce resistance to activated protein C (APCR). Genetic causes are usually recurring and first noticeable in young adulthood.
Conclusions:
There are hereditary and acquired causes of thrombophilia. Evaluating acquired thrombophilia may involve using the clinical history, physical examination, and certain targeted investigations. Hereditary thrombophilia tests are frequently administered ineffectively and non-selectively. Medical professionals should carefully consider the advantages, drawbacks, and unintended consequences before devoting limited resources to the administration of tests that are unlikely to impact clinical management significantly and may cause anxiety. In most VTE (venous thromboembolism) cases, focusing on the clinical history, physical examination, and relevant testing for acquired prothrombotic diseases is appropriate.
